Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

NEXT GENERATION SEQUENCING PANEL FOR FAMILIAL HYPERCHOLESTEROLEMIA AND WHOLE EXOME SEQUENCING LIBRARY PREP SOLUTION

Cardiff and Vale University Health Board

This public procurement record has 2 releases in its history.

Award

27 Jul 2026 at 09:05

UK6 - Contract Award Notice
Award

27 Jul 2026 at 08:49

UK5 - Transparency Notice
Summary of the contracting process

Cardiff and Vale University Health Board procured a next-generation sequencing panel for Familial Hypercholesterolaemia, together with whole-exome sequencing library preparation, associated laboratory reagents, technical support, training and related services. The requirement supports diagnostic testing through the All Wales Genomics Laboratory, including initial and cascade testing within the nationally commissioned All Wales Familial Hypercholesterolaemia service. The service is designed to work with existing laboratory infrastructure, workflows and reporting processes, and includes quality assurance and contingency arrangements to maintain continuity of testing. This is a specialist healthcare diagnostics and laboratory supply requirement, with laboratory reagents as the principal goods category. NHS Wales Shared Services Partnership – Procurement Services managed the procurement for the health board.

The procurement is complete and was awarded through a direct award on technical and intellectual-property grounds. The buyer selected Nonacus as the sole supplier for one completed lot. The award date was 24 July 2026, with a value of £203,154.24 excluding VAT and £243,785.09 including VAT. The contract period runs from 15 April 2027 to 14 April 2029. The direct award rationale states that the proprietary panel and associated intellectual property are exclusively controlled by Nonacus, and that the solution has been extensively validated and integrated into the existing diagnostic pathway. The award was above the relevant threshold. A contract signature milestone was scheduled for 7 August 2026, following a standstill period ending on 6 August 2026.

This award indicates demand for suppliers able to provide clinically validated genomic testing products rather than general laboratory consumables. A credible competitor for a future requirement would need expertise in next-generation sequencing, Familial Hypercholesterolaemia diagnostics and whole-exome sequencing library preparation, together with the ability to supply associated reagents and provide technical support and user training. Compatibility with established laboratory equipment, workflows and reporting systems would be important, as would evidence of analytical and clinical validation within a diagnostic pathway. Suppliers would also need robust quality assurance, contingency planning and service continuity arrangements, and sufficient operational capacity to support a nationally commissioned service handling approximately 600 diagnostic tests each year, including cascade testing.

How relevant is this notice?

Notice Information

Notice Title

NEXT GENERATION SEQUENCING PANEL FOR FAMILIAL HYPERCHOLESTEROLEMIA AND WHOLE EXOME SEQUENCING LIBRARY PREP SOLUTION

Notice Description

The contract is for the provision of a Next Generation Sequencing (NGS) panel, associated reagents, technical support, training and related services to support diagnostic testing for Familial Hypercholesterolaemia (FH) within the All Wales Genomics Laboratory.Nonacus is the sole supplier capable of providing the required proprietary panel and associated services, which have been extensively validated within the existing diagnostic pathway. The solution is fully compatible with current laboratory infrastructure and includes ongoing technical support, quality assurance and contingency arrangements to support continuity of service delivery.The service supports approximately 600 diagnostic tests per annum, including initial and cascade testing, as part of the nationally commissioned All Wales Familial Hypercholesterolaemia service.

Procurement Information

The required Next Generation Sequencing (NGS) panel incorporates proprietary design, content and associated intellectual property rights that are owned and controlled exclusively by the supplier. No other economic operator is authorised to manufacture, supply, licence or support the specific panel required. The intellectual property protections and exclusive rights prevent equivalent products from being supplied by alternative providers. The required solution has been extensively validated within the existing diagnostic pathway and is fully compatible with current laboratory equipment, workflows and reporting processes. No alternative supplier can provide an equivalent validated solution without significant revalidation, implementation effort and associated costs. Introducing an alternative product would require extensive analytical and clinical validation, resulting in delays to service delivery, additional resource requirements and potential risks to continuity of patient testing. The technical characteristics, proven performance and integration requirements mean that competition is absent for technical reasons.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-06d3d0
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/070564-2026
Current Stage
Award
All Stages
Award

Procurement Classification

Notice Type
UK6 - Contract Award Notice
Procurement Type
Standard
Procurement Category
Goods
Procurement Method
Direct
Procurement Method Details
Direct award
Tender Suitability
Not specified
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33696500 - Laboratory reagents

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
£203,154 £100K-£500K
Contracts Value
Not specified

Notice Dates

Publication Date
27 Jul 20262 months ago
Submission Deadline
Not specified
Future Notice Date
Not specified
Award Date
24 Jul 20262 months ago
Contract Period
15 Apr 2027 - 14 Apr 2029 2-3 years
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Complete
Awards Status
Pending
Contracts Status
Not Specified

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
Cardiff and Vale University Health Board
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
CARDIFF
Postcode
CF14 4HH
Postcode Area
Cardiff
Country
Wales
Major Region (ITL 1)
TLL Wales
Basic Region (ITL 2)
TLL5 South East Wales
Small Region (ITL 3)
TLL52 Cardiff and Vale of Glamorgan
Delivery Location
Not specified
Local Authority
Cardiff
Electoral Ward
Heath
Westminster Constituency
Cardiff North

Supplier Information

Number of Suppliers
1
Supplier Name

Nonacus Ltd

Further Information

Notice Documents

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...